Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Tables)

v3.22.2.2
Segment Reporting (Tables)
9 Months Ended
Aug. 31, 2022
Segment Reporting [Abstract]  
Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, and Interest Expense and Assets by Segment

The following table shows, by segment: net revenue, cost of sales, depreciation and amortization, operating profit, and interest expense for the three and nine months ended August 31, 2022 and 2021:

 

 

For the three months ended August 31,

 

 

 

2022

 

 

2021

 

Net revenue:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

7,522,134

 

 

$

7,326,516

 

PrepaCyte CB

 

 

21,000

 

 

 

18,200

 

Public cord blood banking

 

 

137,825

 

 

 

158,936

 

Total net revenue

 

$

7,680,959

 

 

$

7,503,652

 

Cost of sales:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

1,883,400

 

 

$

1,943,419

 

PrepaCyte CB

 

 

10,622

 

 

 

53,498

 

Public cord blood banking

 

 

454,733

 

 

 

462,021

 

Total cost of sales

 

$

2,348,755

 

 

$

2,458,938

 

Operating profit:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

1,268,146

 

 

$

1,941,976

 

PrepaCyte CB

 

 

3,433

 

 

 

(42,193

)

Public cord blood banking

 

 

(317,268

)

 

 

(303,445

)

Total operating profit

 

$

954,311

 

 

$

1,596,338

 

Depreciation and amortization:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

274,598

 

 

$

262,229

 

PrepaCyte CB

 

 

6,945

 

 

 

6,894

 

Public cord blood banking

 

 

360

 

 

 

359

 

Total depreciation and amortization

 

$

281,903

 

 

$

269,482

 

Interest expense:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

365,349

 

 

$

335,870

 

PrepaCyte CB

 

 

 

 

 

 

Public cord blood banking

 

 

 

 

 

 

Total interest expense

 

$

365,349

 

 

$

335,870

 

 

 

 

 

 

 

 

 

 

For the nine months ended August 31,

 

 

 

2022

 

 

2021

 

Net revenue:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

22,159,702

 

 

$

21,224,033

 

PrepaCyte CB

 

 

75,600

 

 

 

56,200

 

Public cord blood banking

 

 

337,405

 

 

 

289,231

 

Total net revenue

 

$

22,572,707

 

 

$

21,569,464

 

Cost of sales:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

5,343,455

 

 

$

5,453,203

 

PrepaCyte CB

 

 

63,934

 

 

 

129,581

 

Public cord blood banking

 

 

1,246,108

 

 

 

1,111,022

 

Total cost of sales

 

$

6,653,497

 

 

$

6,693,806

 

Operating profit:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

4,538,058

 

 

$

5,743,184

 

PrepaCyte CB

 

 

(9,168

)

 

 

(94,065

)

Public cord blood banking

 

 

(909,783

)

 

 

(822,452

)

Total operating profit

 

$

3,619,107

 

 

$

4,826,667

 

Depreciation and amortization:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

818,081

 

 

$

536,823

 

PrepaCyte CB

 

 

20,834

 

 

 

20,683

 

Public cord blood banking

 

 

1,080

 

 

 

661

 

Total depreciation and amortization

 

$

839,995

 

 

$

558,167

 

Interest expense:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

947,968

 

 

$

957,479

 

PrepaCyte CB

 

 

 

 

 

 

Public cord blood banking

 

 

 

 

 

 

Total interest expense

 

$

947,968

 

 

$

957,479

 

 

 

The following table shows the assets by segment as of August 31, 2022 and November 30, 2021:

 

 

 

As of

 

 

As of

 

 

 

August 31, 2022

 

 

November 30, 2021

 

Assets:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell
   service

 

$

56,548,260

 

 

$

50,170,887

 

PrepaCyte CB

 

 

238,636

 

 

 

250,591

 

Public cord blood banking

 

 

9,978,397

 

 

 

10,240,598

 

Total assets

 

$

66,765,293

 

 

$

60,662,076